ENGAGE and EMERGE: Truth and consequences?

The potential benefit of the anti‐amyloid drug aducanumab based on results of recent EMERGE and ENGAGE clinical trials has generated great controversy and has very important implications for the future of anti‐amyloid drug therapies. The two trials of 18‐month duration were done in patients with mil...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alzheimer's & dementia 2021-04, Vol.17 (4), p.692-695
Hauptverfasser:	Kuller, Lewis H., Lopez, Oscar L.
Format:	Artikel
Sprache:	eng
Schlagworte:	aducanumab Aged Alzheimer Disease - drug therapy Alzheimer's disease Amyloid Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers clinical trials Cognitive Dysfunction - drug therapy dementia Dose-Response Relationship, Drug Drug Approval Food and Drug Administration Humans Policy Forum Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!